Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma

Official record

Identifier

NCT07734857

Recruiting locations

Locations are not included in the offline baseline for this record. Open the official record to see the current site list.

Interventions studied

No intervention (observational study)

Lead sponsor

Shanghai Zhongshan Hospital

Target enrolment

100 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Not yet recruiting

First posted

Jul 29, 2026

Last updated on the registry

Jul 29, 2026

Age

18 Years – 80 Years

Sex

ALL

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Age 18-80 years
* Histologically or clinically confirmed unresectable or advanced HCC, classified according to the BCLC staging system
* Planned to receive first-line atezolizumab plus bevacizumab therapy, with no prior systemic therapy for unresectable or advanced HCC
* At least one measurable target lesion with a longest diameter of ≥10 mm on CT or MRI according to RECIST 1.1, with mRECIST assessment performed when applicable
* Availability of baseline and follow-up clinical and radiological data
* Willing and able to provide written informed consent

Exclusion Criteria:

* Presence of another active malignancy, except for malignancies that have been curatively treated and remain recurrence-free
* Prior systemic treatment with immune checkpoint inhibitors or anti-angiogenic agents for unresectable or advanced HCC
* Expected inability to complete the required clinical or radiological follow-up assessments
* Severe comorbid conditions that may interfere with study participation
* No qualified residual blood sample available for planned biomarker analyses because of insufficient volume, contamination, loss, or other sample-related issues
* Any condition deemed unsuitable for participation by the investigator

Indexed under

Liver Cancer